ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress
Study showed targeted tumor uptake with low healthy organ exposure in broad cohort of 207 patients Supports therapeutic potential of ITM's proprietary targeted radiotherapeutic agent Abstract receives prestigious EANM Marie Curie Award, which honors outstanding research contributions in nuclear medicine Barcelona, Spain, October 8, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical […]